← Back to Search

High intensity exercise for Hypertrophic Cardiomyopathy

N/A

Waitlist Available

Led By Benjamin D Levine, MD

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up five months

Awards & highlights

Study Summary

This trial found that regular moderate to vigorous intensity exercise improves exercise capacity and cardiorespiratory fitness in patients with hypertrophic cardiomyopathy, and does not increase arrhythmia burden or adverse events.

Eligible Conditions

Hypertrophic Cardiomyopathy

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ ten months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~ten months

This trial's timeline: 3 weeks for screening, Varies for treatment, and ten months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cardiorespiratory fitness

Secondary outcome measures

Functional diastolic reserve

Safety - Number of adverse events

Safety - Number of arrhythmic events

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: High intensity exerciseExperimental Treatment1 Intervention

A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions will supervised at our hospital based fitness centre until the subject is confident to complete the training independently. All HIIT sessions will be supervised over the intervention.

Group II: Moderate intensity exerciseActive Control1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

High intensity exercise

2013

N/A

~350

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor

1,048 Previous Clinical Trials

1,053,746 Total Patients Enrolled

American Heart AssociationOTHER

326 Previous Clinical Trials

4,933,597 Total Patients Enrolled

American College of Sports MedicineOTHER

11 Previous Clinical Trials

320 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor open to individuals of advanced age?

"Participants must be aged between 18 and 80 to participate in this trial. For those younger than 18 or older than 65, there are 25 medical trials and 194 clinical studies respectively that may better suit them."

Answered by AI

Who is the ideal candidate for this experimental program?

"This clinical trial seeks 20 individuals suffering from hypertrophic cardiomyopathy whose age ranges between 18 and 80 years. Importantly, the study is open to both genders who meet this requirement."

Answered by AI

Are there opportunities for individuals to enroll in this research experiment?

"According to clinicaltrials.gov, this medical trial is not presently recruiting patients. Originally posted on the 31st of January 2018 and last revised on August 23rd 2022, it appears that the study has concluded its recruitment phase; however there are still 219 other trials enrolling participants at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

High Intensity Exercise for Increasing Fitness in Patients With Hypertrophic Cardiomyopathy

Benjamin Levine 2018. "High Intensity Exercise for Increasing Fitness in Patients With Hypertrophic Cardiomyopathy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03335332.